The ability of third-generation EGFR-TKIs to control intracranial lesions in EGFR-mutated advanced NSCLC patients is accompanied by significant CNS toxicities such as headaches, dizziness, and cognitive impairments due to enhanced drug penetration across the blood-brain barrier 38. This evidence concerns the gene EGFR and non-small cell lung carcinoma.